Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection (Q45107740)

From Wikidata

Jump to navigation Jump to search

scientific article published on October 31, 2011

Language	Label	Description	Also known as
English	Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection	scientific article published on October 31, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

influenza vaccine

1 reference

based on heuristic

inferred from title

mucosal immune system

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22051136

16 December 2024

author name string

Seol Hee Hong

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Young-Ho Byun

2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Chung Truong Nguyen

3

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Soo Young Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Baik Lin Seong

5

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Songyong Park

6

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Gyu-Jin Woo

7

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Yeup Yoon

8

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Jeong Tae Koh

9

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Kohtaro Fujihashi

10

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Joon Haeng Rhee

11

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Shee Eun Lee

12

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

language of work or name

0 references

publication date

31 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

full work available at URL

https://api.elsevier.com/content/article/PII:S0264410X11016951?httpAccept=text/xml

1 reference

10.1016/J.VACCINE.2011.10.058

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

16 December 2024

https://api.elsevier.com/content/article/PII:S0264410X11016951?httpAccept=text/plain

1 reference

10.1016/J.VACCINE.2011.10.058

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

16 December 2024

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

466-474

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Influenza Vaccines for the Future

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

A review of vaccine research and development: human acute respiratory infections.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Estimating influenza-associated deaths in the United States

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Mucosal immunity and vaccines

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Vaccination strategies to promote mucosal antibody responses.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine influenza virus vaccine administered intranasally in pigs

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Epidemiology of pandemic influenza: use of surveillance and modeling for pandemic preparedness

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Influenza vaccination among the elderly in the United States

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Defending the mucosa: adjuvant and carrier formulations for mucosal immunity

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Mucosal adjuvants

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Pathogen recognition and innate immunity

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Recognition of microorganisms and activation of the immune response

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

TLR-based immune adjuvants.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Role of secretory antibodies in the defence against infections

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Cross‐Reactive H1N1 Antibody Responses to a Live Attenuated Influenza Vaccine in Children: Implication for Selection of Vaccine Strains

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Inhibition of airway allergic disease by co-administration of flagellin with allergen

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Course of seasonal influenza A/Brisbane/59/07 H1N1 infection in the ferret

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Sublingual vaccination with influenza virus protects mice against lethal viral infection

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Type I Interferon Signaling Regulates Ly6Chi Monocytes and Neutrophils during Acute Viral Pneumonia in Mice

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Co-administration of cholera toxin and apple polyphenol extract as a novel and safe mucosal adjuvant strategy.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

7 January 2021

Haemagglutination-inhibiting antibody to influenza virus

45

1 reference

10.1016/J.VACCINE.2011.10.058

https://api.crossref.org/works/10.1016/J.VACCINE.2011.10.058

16 December 2024

Identifiers

10.1016/J.VACCINE.2011.10.058

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45107740&oldid=2288261719"